Table 1.
Evaluation of drug combinations for inhibition of HIV-1 in MT-2 cell culture.
| Combinations | Analysis Method | ||
| Median-Effecta (Combination Index) |
MacSynergyb (Synergy/Antagonism Volumes μM2%) |
Isobologramc (ADA, p value) |
|
| TFV+FTC | synergy (0.52 ± 0.08) | strong synergy (181 ± 30/-36 ± 10) | synergy (-0.37, 0.001) |
| TFV+EFV | synergy (0.51 ± 0.14) | strong synergy (267 ± 50/-13 ± 5) | synergy (-0.14, 0.027) |
| FTC+EFV | synergy (0.59 ± 0.11) | moderate synergy (90 ± 30/0 ± 10) | synergy (-0.23, 0.001) |
| TFV+FTC+EFV | synergy (0.56 ± 0.12) | NDd | ND |
a The drugs were mixed at 1:1 IC50 ratios. Definition of the degrees of synergy is described in Methods. The values are averages of more than three independent measurements.
b Synergy/antagonism volumes were calculated at the 95% confidence level. Definition of the degrees of synergy is described in Methods.
c Synergy is defined by a negative ADA (the average deviation from dose-wise additivity) value with p value ≤ 0.05.
dND = not determined.